SAB Biotherapeutics Files 8-K on Warrants

TL;DR

SAB Biotherapeutics filed an 8-K detailing warrants exercisable at $11.50.

AI Summary

On December 29, 2025, SAB Biotherapeutics, Inc. filed an 8-K report. The filing indicates that the company, formerly known as Big Cypress Acquisition Corp. until November 20, 2020, is involved in the biological products sector. The report details information related to warrants exercisable for common stock at an exercise price of $11.50 per share.

Why It Matters

This filing provides an update on SAB Biotherapeutics' financial instruments, specifically warrants, which could impact future share dilution and investor decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of existing financial instruments and does not report any new material events or significant financial changes.

Key Numbers

• $11.50 — Warrant Exercise Price (Price at which warrants can be exercised for common stock.)

Key Players & Entities

• SAB Biotherapeutics, Inc. (company) — Registrant
• Big Cypress Acquisition Corp. (company) — Former Company Name
• 20201120 (date) — Date of Name Change
• 20251229 (date) — Date of Report
• $11.50 (dollar_amount) — Warrant Exercise Price

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
• $75,000,000 — ng an aggregate offering price of up to $75,000,000 (the "Placement Shares"). The Placement
• $20 m — res of common stock for an amount up to $20 million, pursuant to that certain Sales A

Filing Documents

• sabs-20251229.htm (8-K) — 47KB
• 0001193125-25-335267.txt ( ) — 186KB
• sabs-20251229.xsd (EX-101.SCH) — 46KB
• sabs-20251229_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events. Establishment of "At the Market Offering" Program On December 29, 2025, SAB Biotherapeutics, Inc. (the "Company") entered into a Sales Agreement (the " Agreement " ) with UBS Securities LLC (the "Agent") with respect to an at-the-market offering program under which the Company may offer and sell from time to time through or to the Agent, as sales agent or principal, the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $75,000,000 (the "Placement Shares"). The Placement Shares will be registered under the Securities Act of 1933, as amended (the "Securities Act"), and will be offered and sold pursuant to a shelf registration statement on Form S-3. The Company intends to use the net proceeds from the offering, if any, to support pipeline development and for general corporate and working capital purposes. The Company is not obligated to sell any Placement Shares pursuant to the Agreement. Subject to the terms and conditions of the Agreement, the Agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market LLC ("Nasdaq"), to sell the Placement Shares from time to time based upon the Company's instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. Sales of the Placement Shares, if any, will be made on Nasdaq at market prices by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) of the Securities Act. The Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to the Agreement, an amount up to 3% of the aggregate gross proceeds from each sale of Placement Shares. The offering of the Placement Shares pursuant to the Agreement will terminate upon the termination of the Agreement as permitted therein. The Agreement m

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: December 29, 2025 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR